BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524632

SHUKRAPHAR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Shukra Pharmaceuticals Share Price Update

As of the latest trading session, Shukra Pharmaceuticals share price is currently at ₹ 34.41, which is up by ₹ 0.66 from its previous closing. Today, the stock has fluctuated between ₹ 34.41 and ₹ 34.41. Over the past year, Shukra Pharmaceuticals has achieved a return of 373.21 %. In the last month alone, the return has been 23.86 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Shukra Pharmaceuticals fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    1,506.70

  • P/E Ratio (TTM)

    146.70

  • Beta

    -0.23

  • Book Value / share

    1.43

  • Return on equity

    15.90%

  • EPS (TTM)

    0.23

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    1.03

info icon alternate text

Shukra Pharmaceuticals Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 5.39
Operating Expense 5.13
Net Profit 1.03
Net Profit Margin (%) 19.10
Earnings Per Share (EPS) 0.02
EBITDA 2.43
Effective Tax Rate (%) 24.81
Particulars MAR 2025 (Values in Cr)
Revenue 13.27
Operating Expense 7.16
Net Profit 5.39
Net Profit Margin (%) 40.61
Earnings Per Share (EPS) 0.12
EBITDA 8.78
Effective Tax Rate (%) 28.79
Particulars DEC 2024 (Values in Cr)
Revenue 10.58
Operating Expense 7.49
Net Profit 3.16
Net Profit Margin (%) 29.86
Earnings Per Share (EPS) 0.72
EBITDA 4.94
Effective Tax Rate (%) 22.73
Particulars SEP 2024 (Values in Cr)
Revenue 5.56
Operating Expense 5.70
Net Profit 0.54
Net Profit Margin (%) 9.71
Earnings Per Share (EPS) 0.12
EBITDA 1.68
Effective Tax Rate (%) 39.08
Particulars JUN 2024 (Values in Cr)
Revenue 3.18
Operating Expense 3.10
Net Profit 0.49
Net Profit Margin (%) 15.40
Earnings Per Share (EPS) 0.11
EBITDA 1.53
Effective Tax Rate (%) 38.74
Particulars MAR 2025 (Values in Cr)
Revenue 32.59
Operating Expense 23.45
Net Profit 9.58
Net Profit Margin (%) 29.39
Earnings Per Share (EPS) 0.22
EBITDA 16.93
Effective Tax Rate (%) 28.18
Particulars MAR 2024 (Values in Cr)
Revenue 74.57
Operating Expense 57.51
Net Profit 18.54
Net Profit Margin (%) 24.86
Earnings Per Share (EPS) 16.93
EBITDA 22.22
Effective Tax Rate (%) 6.79
Particulars MAR 2023 (Values in Cr)
Revenue 58.83
Operating Expense 55.59
Net Profit 4.41
Net Profit Margin (%) 7.49
Earnings Per Share (EPS) 11.23
EBITDA 6.56
Effective Tax Rate (%) 0.90
Particulars MAR 2022 (Values in Cr)
Revenue 20.49
Operating Expense 19.55
Net Profit 0.75
Net Profit Margin (%) 3.66
Earnings Per Share (EPS) 4.79
EBITDA 2.96
Effective Tax Rate (%) 26.47
Particulars MAR 2021 (Values in Cr)
Revenue 11.20
Operating Expense 11.26
Net Profit 0.03
Net Profit Margin (%) 0.26
Earnings Per Share (EPS) 0.22
EBITDA 1.60
Effective Tax Rate (%) 60.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 1.44
ROE % 15.90
ROCE % 21.76
Total Debt to Total Equity 0.06
EBITDA Margin 51.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 52.65
ROE % 44.71
ROCE % 44.16
Total Debt to Total Equity 0.10
EBITDA Margin 29.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 64.63
ROE % 21.18
ROCE % 18.84
Total Debt to Total Equity 0.20
EBITDA Margin 11.15
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.43
ROE % 4.69
ROCE % 5.81
Total Debt to Total Equity 0.41
EBITDA Margin 14.49
Particulars MAR 2021 (Values in Cr)
Book Value / Share 99.63
ROE % 0.90
ROCE % 1.35
Total Debt to Total Equity 0.57
EBITDA Margin 16.07
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 12.11
Total Assets 86.76
Total Liabilities 86.76
Total Equity 62.83
Share Outstanding 437879440
Price to Book Ratio 15.17
Return on Assets (%) 11.03
Return on Capital (%) 14.29
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.98
Total Assets 77.83
Total Liabilities 77.83
Total Equity 57.63
Share Outstanding 10959725
Price to Book Ratio 6.20
Return on Assets (%) 23.81
Return on Capital (%) 30.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.97
Total Assets 74.96
Total Liabilities 74.96
Total Equity 25.29
Share Outstanding 1565700
Price to Book Ratio 0.73
Return on Assets (%) 5.87
Return on Capital (%) 14.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.28
Total Assets 35.11
Total Liabilities 35.11
Total Equity 16.35
Share Outstanding 1565700
Price to Book Ratio 0.58
Return on Assets (%) 2.13
Return on Capital (%) 3.81
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.50
Total Assets 35.60
Total Liabilities 35.60
Total Equity 15.59
Share Outstanding 1565675
Price to Book Ratio 0.45
Return on Assets (%) 0.52
Return on Capital (%) 0.74
Particulars MAR 2025 (Values in Cr)
Net Income 13.33
Cash from Operations 11.67
Cash from Investing -1.26
Cash from Financing -4.51
Net change in Cash 2.13
Free Cash Flow 14.42
Particulars MAR 2024 (Values in Cr)
Net Income 19.88
Cash from Operations -4.57
Cash from Investing -1.20
Cash from Financing 12.40
Net change in Cash 6.00
Free Cash Flow -2.81
Particulars MAR 2023 (Values in Cr)
Net Income 4.44
Cash from Operations 3.41
Cash from Investing -4.42
Cash from Financing 4.94
Net change in Cash 3.68
Free Cash Flow 7.91
Particulars MAR 2022 (Values in Cr)
Net Income 1.01
Cash from Operations 8.42
Cash from Investing -1.52
Cash from Financing -6.67
Net change in Cash -0.21
Free Cash Flow 9.97
Particulars MAR 2021 (Values in Cr)
Net Income 0.09
Cash from Operations 0.53
Cash from Investing -1.89
Cash from Financing 1.73
Net change in Cash 0.37
Free Cash Flow 2.32
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 35.34 14.42 1.93 270.82 30.00 / 68.00
BLISS GVS PHARMA LTD 159.15 15.77 1.60 1681.41 105.05 / 190.65
CIPLA LTD 1561.55 23.39 4.04 126136.65 1310.05 / 1694.95
FERMENTA BIOTECH LIMITED 300.35 8.46 2.43 883.96 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2764.05 49.45 23.99 46824.67 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 35.34 19.21 5.58 270.82 30.00 / 68.00
AMRUTAJAN HEALTH LTD 701.75 37.21 6.21 2028.80 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9271.90 109.61 30.08 23179.75 6222.35 / 10653.05
BLISS GVS PHARMA LTD 159.15 23.82 1.58 1681.41 105.05 / 190.65

Shukra Pharmaceuticals shareholding pattern

Holding

Others
48.92%
Promoter Holdings
50.95%
FII
0.0%
DII
0.11%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Renuka Yogesh Parikh 8.4E7 (19.18%) Public Shareholding
Yogesh Biharilal Parikh 8.4E7 (19.18%) Public Shareholding
Anar Project Private Limited 8.224E7 (18.78%) Shareholding of Promoter and Promoter Group
Parshva Texchem India Private Ltd. 7.51756E7 (17.17%) Shareholding of Promoter and Promoter Group
Navkar Surgical Gujarat 5.16E7 (11.78%) Shareholding of Promoter and Promoter Group
Dakshesh Rameshchandra Shah 4360000.0 (1.0%) Shareholding of Promoter and Promoter Group
Anar Jayeshbhai Patel 4360000.0 (1.0%) Shareholding of Promoter and Promoter Group
Sujay Jyotindra Mehta 3120000.0 (0.71%) Shareholding of Promoter and Promoter Group
Payal Sujay Mehta 2280000.0 (0.52%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

Shukra Pharmaceuticals Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
34.41 1.98 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 33.50
  • 26 Days 31.20
  • 10 Days 33.40
  • 50 Days 28.00
  • 12 Days 33.20
  • 100 Days 24.10
  • 20 Days 32.10
  • 200 Days 20.20
33.74 PIVOT

First Support

33.74

First Resistance

33.74

Second Support

33.74

Second Resistance

33.74

Third Support

33.74

Third Resistance

33.74

RSI

65.93

ADX

48.74

MACD

1.97

Williams % R

-53.13

Commodity Channel Index (CCI)

45.45

Date

2025-10-10

Week

197792.00

Same Day

101574.00

Month

184789.00

1 Year

-0.23

3 Year

0.14

Over 1 Month

23.86%

down

Over 1 Year

373.21%

down

Over 3 Months

69.03%

down

Over 3 Years

215.92%

down

Over 6 Months

81.20%

down

Over 5 Years

160.73%

down

Shukra Pharmaceuticals Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2025 0.01 Final 18 Sep 2025 Equity shares
23 Sep 2024 1.0 Final 24 Sep 2024 Equity shares
15 Sep 2023 0.5 Final 16 Sep 2023 Equity shares
22 Sep 2022 0.5 Final 22 Sep 2022 Equity shares
19 Sep 2019 0.5 Final 21 Sep 2019 Equity shares
31 Aug 2018 0.5 Final 04 Sep 2018 Equity shares
01 Sep 2017 0.5 Final 05 Sep 2017 Equity shares
Ex-Date Ex-Bonus Ratio
20 Apr 2024 19 Apr 2024 3:1
Ex-Date Old FV NEW FV Record Date
21 Mar 2025 10.0 1.0 21 Mar 2025

Shukra Pharmaceuticals Share Price

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016. The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing.

The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat.

The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.

The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals companies around the world.

In FY 2013-14, the Company got approval from Hon'ble High Court of Gujarat for revival of Relish Pharmaceuticals Limited and Amalgamation of Proper Dealcomm Private Limited with the erstwhile Relish Pharmaceuticals Limited and Re-organization of Share Capital of Relish Pharmaceuticals Limited through the Scheme of Arrangement vide Hon'ble High Court of Gujarat order dated 20 December, 2013.

The Company has achieved WHO-GMP certification, successfully securing a partnership with Meril Healthcare for robotic surgery projects in October 2025.

Parent organization Indian Private
NSE symbol [-]
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Shukra Pharmaceuticals Ltd?

Answer Field

Shukra Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 34.41 as on Oct 13 2025 03:15 PM.

What is the Market Cap of Shukra Pharmaceuticals Ltd Share?

Answer Field

The market cap of Shukra Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 1,506.70 as on Oct 13 2025 03:15 PM.

What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Shukra Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 35.86 and ₹ 5.75.

What is 1 year return for Shukra Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 373.21%.

What is the P/E Ratio of Shukra Pharmaceuticals Ltd Share?

Answer Field

As on Oct 13 2025 03:15 PM the price-to-earnings (PE) ratio for Shukra Pharmaceuticals Ltd share is 146.70.

What is the PB ratio of Shukra Pharmaceuticals Ltd Share?

Answer Field

As on Oct 13 2025 03:15 PM, the price-to-book (PB) ratio for Shukra Pharmaceuticals Ltd share is 1.43.

How to Buy Shukra Pharmaceuticals Ltd Share?

Answer Field

You can trade in Shukra Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Shukra Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Shukra Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Shukra Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59